What is the current stock price of Aethlon Medical, Inc. (AEMD)?

As of the latest market data, Aethlon Medical, Inc. (AEMD) is trading at $2.17. The stock has seen a loss of -2.25% today.

Does Aethlon Medical, Inc. (AEMD) pay a dividend?

Based on current data, Aethlon Medical, Inc. does not have a confirmed active dividend policy.

What is the market cap of Aethlon Medical, Inc.?

The current market capitalization of Aethlon Medical, Inc. (AEMD) is approximately unavailable.

AEMD

Aethlon Medical, Inc.·Healthcare

2.17

2.252%(−0.05)

Market Closed

2.44

12.442%(+0.27)

After Hours

Last Updated: — ET

52W L: $1.3652W H: $35.20

AEMD NEWS

feeds.newsfilecorp.com

Mar 24

Advancements in Novel Immunotherapeutics in The Oncology Battle

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry

prnewswire.com

Mar 24

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure".

prnewswire.com

Mar 12

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process. The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.

globenewswire.com

Mar 6

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com

prnewswire.com

Feb 23

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET.

seekingalpha.com

Feb 19

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Company Profile

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

1999-03-04

Beta

1.52

Websitewww.aethlonmedical.com↗